LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.
The study is a randomised, placebo-controlled clinical trial involving 110 patients across 40 clinical trial sites in the US, the company explained.
Patients with stable post-stroke disability are enrolled 6 to 12 months after their stroke and are randomised to receive either the CTX therapy or placebo treatment.
The study's primary end-point is a comparison between improvement in arms mobility between the treatment and the placebo.
Top-line results from the study are expected in early 2020.
ReNeuron shares were trading down 0.6% at 50.22 pence each.
Reneuron (RENE)